US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

39.67

+0.41001.04%

Post-market: 39.840.1700+0.43%16:19 EDT

Volume:74.95K

Turnover:2.96M

Market Cap:259.84M

PE:- -

High:39.69

Open:39.05

Low:39.05

Close:39.26

52wk High:41.49

52wk Low:22.18

Shares:6.55M

Float Shares:6.55M

Volume Ratio:0.54

T/O Rate:1.14%

Dividend:0.28

Dividend Rate:0.71%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna's Big Win

BioNTech on Track for Worst Day Since March After Ending Colorectal Cancer Trial

Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

Moderna Stock Falls on $2B Notes Deal: Is the Cancer Rally Still Intact?

Argus Research Upgrades Moderna to Buy From Hold, $180 Price Target

MT Newswires Live

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Moderna Price Target Announced at $180.00/Share by Argus Research

U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty

Success After a Century of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough

Moderna Prices $2.6 Billion Convertible Notes due 2032

MT Newswires Live

Moderna Rises After Upsized $2.6 Bln Convertible Bond Sale

Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil

MT Newswires Live

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Twist Bioscience CEO Emily Leproust Sells USD 6.28 Million in Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IDNA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":39.67,"timestamp":1788292800000,"preClose":39.26,"halted":0,"volume":74945,"hourTrading":{"tag":"盘后","latestPrice":39.84,"preClose":39.67,"latestTime":"16:19 EDT","volume":13,"amount":515.8799750000001,"timestamp":1788293960884,"change":0.17,"changeRate":0.004285,"amplitude":0.004285},"delay":0,"changeRate":0.010443199184921134,"floatShares":6550000,"shares":6550000,"eps":0,"marketStatus":"Post-Mkt","change":0.41,"latestTime":"09-01 16:20:45 EDT","open":39.05,"high":39.6899,"low":39.05,"amount":2955566.5439299997,"amplitude":0.016299,"askPrice":46.94,"askSize":100,"bidPrice":39.3,"bidSize":30,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":39.26,"sharesOutstanding":5100000,"nav":39.224094,"aum":256917815.7,"dividendRate":0.007131,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":39.96,"preClose":39.26,"latestTime":"09:08 EDT","volume":3,"amount":119.110005,"timestamp":1788268100857,"change":0.7,"changeRate":0.01783,"amplitude":0.018085},"postHourTrading":{"tag":"盘后","latestPrice":39.84,"preClose":39.67,"latestTime":"16:19 EDT","volume":13,"amount":515.8799750000001,"timestamp":1788293960884,"change":0.17,"changeRate":0.004285,"amplitude":0.004285},"volumeRatio":0.538616,"impliedVol":0.0718,"impliedVolPercentile":0.0556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6550000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.538616,"shares":6550000,"dividePrice":0.2829,"high":39.6899,"amplitude":0.016299,"preClose":39.26,"low":39.05,"week52Low":22.18,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":39.67,"committee":-0.538462,"eps":0,"divideRate":0.007131,"volume":74945,"delay":0,"ttmEps":0,"open":39.05,"prevYearClose":26.19,"prevWeekClose":39.29,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":41.48,"twentyDayClose":32.9055,"sixtyDayClose":29.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663018217","title":"BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna's Big Win","url":"https://stock-news.laohu8.com/highlight/detail?id=2663018217","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663018217?lang=en_us&edition=fundamental","pubTime":"2026-08-29 02:44","pubTimestamp":1787942640,"startTime":"0","endTime":"0","summary":"BioNTech stock fell sharply on Friday after the company announced it had scrapped a clinical trial for its mRNA cancer vaccine, marking the second setback in months.The German biotech and partner Gene","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","IDNA","BK4532","BK4568","BK4588","BK4139","BK4551","BNTX","MRNA","BK4533","WDNA","BK4548","BK4534","BK4535","BK4501","BK4585","GNOM","LGHT","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663097770","title":"BioNTech on Track for Worst Day Since March After Ending Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663097770","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663097770?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:46","pubTimestamp":1787935618,"startTime":"0","endTime":"0","summary":"BUZZ-BioNTech on track for worst day since March after ending colorectal cancer trialUpdates** U.S.-listed shares of German drugmaker BioNTechBNTX.O22UAy.DEfall 7.4% to $103.07, putting the stock on c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4N44P1BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4501","LGHT","BK4532","MRNA","BNTX","BK4535","BK4534","IDNA","BK4551","BK4139","BK4533","MRNX","GNOM","WDNA","BK4568","BK4588","BK4585","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663097210","title":"Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663097210","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663097210?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:30","pubTimestamp":1787934634,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. Vertex’s new Phase 1 study, officially titled “A Phase 1, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-tests-vx-407s-impact-on-birth-control-what-it-means-for-vrtx-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-tests-vx-407s-impact-on-birth-control-what-it-means-for-vrtx-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BBH","GNMX","IE0002270589.USD","IE00B19Z3581.USD","PBE","VERX","LU1674673428.USD","LU2237438978.USD","IBBQ","BK4023","LU2362541513.USD","LU2417539215.USD","LU2468319806.SGD","SG9999001176.USD","VRTX","ISBC","LU1585245621.USD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","LU0889565916.HKD","SG9999001176.SGD","LU1430594728.SGD","BK4588","LU0566484027.USD","LU0823416689.USD","IDNA","LU2362541273.HKD","BK4532","LU0417517546.SGD","LU0058720904.USD","TBXU","IE0009355771.USD","LU2089984988.USD","SG9999013999.USD","LU1815336091.USD","LU1559883803.SGD","IBB","LU0320765992.SGD","BK4211","BIB","LU2324357040.USD","IE00B894F039.SGD","LU1093756325.SGD","IE00BJT1NW94.SGD","BK4567","IE00B19Z9Z06.USD","LU2362540622.SGD","BK4139","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663975310","title":"Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663975310","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663975310?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:18","pubTimestamp":1787933923,"startTime":"0","endTime":"0","summary":"Revolution Medicines  should post \"strong launch numbers\" for pancreatic cancer drug Rasonque , which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.UBS raise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","RVMD","IE0002141913.USD","CANC","LU0109394709.USD","PTH","BBH","BK4139","IDNA","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662094399","title":"mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2662094399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662094399?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:55","pubTimestamp":1787928925,"startTime":"0","endTime":"0","summary":"After BioNTech (BNTX) announced the discontinuation of its Phase 2 study partnered with Roche (RHHBY) of autogene cevumeran, an individualized mRNA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mrna-immunotherapy-discontinuation-a-negative-for-biontech-says-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mrna-immunotherapy-discontinuation-a-negative-for-biontech-says-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRTS","RHHBY","BK4588","BK4139","03165","BK4548","BK4007","BK4568","BK4551","CANC","BNTX","BK4535","IDNA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662091557","title":"Moderna Stock Falls on $2B Notes Deal: Is the Cancer Rally Still Intact?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662091557","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662091557?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:00","pubTimestamp":1787925600,"startTime":"0","endTime":"0","summary":"TradingKey - MRNA closed at $142.77 after a $2B convertible-notes plan. Phase 3 melanoma success is powerful, but dilution and cash burn raise the stakes for investors.\n","market":"sg","thumbnail":"https://resource.tradingkey.com/uploads/20260510/Moderna-288a1cc7991e4f03bba2bb41856a0806.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260510/Moderna-288a1cc7991e4f03bba2bb41856a0806.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262138360-moderna-stock-2b-notes-cancer-vaccine-rally-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","LGHT","BK4568","BK4532","WDNA","BK4551","BK4501","BK4139","BK4534","IDNA","MRNA","BK4585","MRNY","MRNX","GNOM","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098660","title":"Argus Research Upgrades Moderna to Buy From Hold, $180 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662098660?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:20","pubTimestamp":1787919631,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $96.47, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4501","IDNA","MRNY","GNOM","BK4551","BK4534","BK4533","BK4568","BK4532","LGHT","WDNA","BK4585","MRNX","BK4139","MRNA","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098595","title":"Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098595","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662098595?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:15","pubTimestamp":1787919300,"startTime":"0","endTime":"0","summary":"Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending PatentsDOYLESTOWN, Pa., Aug.  28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352669/0/en/aprea-therapeutics-announces-expansion-of-intellectual-property-portfolio-for-precision-oncology-programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","BK4539","GDOC","LENZ","BK4007","BK4139","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060019","title":"Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060019?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:12","pubTimestamp":1787919133,"startTime":"0","endTime":"0","summary":"BRIEF-Moderna Announces Pricing Of Upsized $2.6 Billion Offering Of Convertible Senior NotesAug 28 -Moderna IncMRNA.O:MODERNA: MODERNA ANNOUNCES PRICING OF UPSIZED $2.6 BILLION OFFERING OF CONVERTIBLE SENIOR NOTESMODERNA: PURCHASED HEDGE OVERLAY INTENDED TO OFFSET DILUTION UP TO CAP INITIALLY EQUAL TO 175.0% PREMIUM TO STOCK PRICE AT PRICINGSource text: [ID:]Further company coverage:MRNA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P0W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","MRNY","BK4532","BK4534","BK4588","BK4501","BK4139","IDNA","LGHT","MRNX","WDNA","BK4551","BK4568","BK4585","GNOM","BK4533","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060438","title":"Moderna Price Target Announced at $180.00/Share by Argus Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060438?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:00","pubTimestamp":1787918400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRNA/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","BK4501","BK4585","BK4534","BK4551","BK4532","GNOM","BK4139","IDNA","MRNX","BK4533","BK4588","BK4568","WDNA","BK4548","MRNA","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662677510","title":"U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty","url":"https://stock-news.laohu8.com/highlight/detail?id=2662677510","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662677510?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:41","pubTimestamp":1787917296,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta BeautyAugust 28 (Reuters)-Futures tied to the S&P 500 and Nasdaq inched lower on Friday after Nvidia's stellar forecast sparked a technology ra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL6N44P0MR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","SG9999002224.SGD","07388","GNOM","IE00B775SV38.USD","NVDY","NVIW.SI","LU2491049909.HKD","LU2238339852.HKD","LU1868836591.USD","LU0057025933.USD","LU1868837300.USD","LU2298064838.USD","LU1880398471.USD","LU0823434740.USD","LU1974910355.USD","LU2430703095.HKD","LU0640476718.USD","SGXZ99366536.SGD","LU2471134952.CNY","NERD","BK4085","LU2023251221.USD","LU2237443622.USD","LU0210528500.USD","LU0011850046.USD","LU2125909759.SGD","LU0267386448.USD","LU2168564065.EUR","THMR","LU0985320562.USD","LU2347655156.SGD","LU2108987350.USD","HK0000306685.HKD","LU2237957902.USD","LU1645745479.HKD","SG9999014906.USD","LU2264538146.SGD","MRNX","LU0689626769.HKD","LU1979441026.SGD","IE00BMPRXN33.USD","BK4608","LU0724617625.USD","LU2458330243.SGD","LU2106854487.HKD","LU2347655073.USD","IE00B775H168.HKD","LU2999663052.SGD","LU2047632596.USD","SMHX","HK0000304797.USD","LU0174119429.USD","STBQ","IE00B1BXHZ80.USD","HK0000914660.USD","LU0868494617.USD","LU1316542783.SGD","LU0689472784.USD","SG9999014914.USD","USXF","LU0077335932.USD","LU1935043023.USD","BKCH","XLC","LU0965509010.AUD","LU2552382132.HKD","IPAY","SG9999014880.SGD","BK4548","LU1003077747.HKD","LU1153585028.USD","LU0308772762.SGD","LU2125909916.SGD","LU1633808545.USD","IE00B7KXQ091.USD","LU2896262040.SGD","LU2023250330.USD","LU0708995401.HKD","LU2065170008.USD","LU0672654240.SGD","LU2191332357.HKD","LU0143551892.USD","PYPU","LU0211328371.USD","LU1868837136.USD","LU1366333091.USD","IE00BMPRXQ63.HKD","LU0889565833.HKD","LU1242518931.SGD","LU1496350502.SGD","SGXZ81514606.USD","BK4585","LU1043141123.HKD","LU1989764748.USD","LU0965509283.SGD","LFGY","LU0310800379.SGD","LU0170899867.USD","LU0390134368.USD","LU2357305700.SGD","LU2213496289.HKD","LU1145028129.USD","LU1815333072.USD","BK4612","LU0545039389.USD","LU3102509885.SGD","LU1548497426.USD","LU2148611432.USD","LU1066051498.USD","LU0053666078.USD","BK4527","BK4595","LU0094547139.USD","2NVD.UK","NVDG","LU1400636574.HKD","BK4614","HK0000532082.HKD","LU1791710582.SGD","SPTE","LU2756315318.SGD","XLK","IE00BWXC8680.SGD","IE00B19Z9505.USD","LU1917777945.USD","LU0289961442.SGD","LU1037948541.HKD","LU0353189680.USD","LU0788109477.HKD","LU1935042215.USD","LU2237443465.HKD","AFRM","BK4109","LU2272731865.HKD","WGMI","LU1861220033.SGD","LU1815336760.USD","LU2381873111.SGD","LU1989772923.USD","LU2087621335.USD","NVDX","PYPY","LU1084165304.USD","LU2089985449.USD","NVDW","LU2237443895.HKD","LU0426412945.USD","BK4501","IE00B4YYXB79.USD","SG9999018857.SGD","LU0444973449.USD","LU0079474960.USD","LU0683600562.USD","LU0942090050.USD","LU2452424414.USD","LU0912757837.SGD","IREG","LU2552382058.USD","SG9999015341.SGD","LU0494093205.USD","LU0708994859.HKD","LU2089283258.USD","LU0265550946.USD","HK0000304805.HKD","IE0034235303.USD","LU1116320901.HKD","ESUM","IE00BQXX3F31.USD","LU2750360997.AUD","LU2125910179.SGD","LU2249611893.SGD","LU2552382215.SGD","LU0786609619.USD","LU0823414478.USD","ESPO","LU0082616367.USD","SG9999001424.SGD","LU2637965513.SGD","LU1868836757.USD","NVDU","SG9999004303.SGD","LU0476273544.USD","TTEQ","IE00B3S45H60.SGD","LU2360107168.USD","LU2357125470.USD","LU1923622291.USD","IE00BKPKM429.USD","LU0096364046.USD","BK4588","ARTY","LU2462157665.USD","HK0000914686.HKD","LU2592432038.USD","LU1066053197.SGD","SG9999017495.SGD","SG9999015945.SGD","IE00BYXW3230.USD","SOXQ","07788","LU0265550359.USD","LU2394011477.USD","LU2279689827.SGD","LU2065169927.USD","NVDS","IE0001KFT4U8.USD","AFRU","IETC","LU2089284900.SGD","DAPP","LU1169589451.USD","IE00B19Z9Z06.USD","LU2168563687.JPY","LU1323610961.USD","LU2403377893.USD","LU2931357623.SGD","LU0158827781.USD","LU1551013342.USD","LU0138981039.USD","ESLG","IE00BZ9MQY76.HKD","S","LU2272731600.USD","LU1435385759.SGD","LU1400636491.USD","IE00BJTD4V19.USD","LU0109392836.USD","NVD3.UK","LU1803068623.USD","CLSE","BK4566","HK0000320223.HKD","LU2168564149.EUR","LU2471134796.USD","LU2430703251.USD","LU2746668974.SGD","LU1242518857.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","FDTX","LU0106831901.USD","LU2322448957.HKD","LU1244550221.USD","LU2462591350.SGD","MNRS","BK4200","IREN","LU0266013472.USD","LU2420271590.USD","LU1551013425.SGD","LU2250418816.HKD","SGXZ51526630.SGD","LU0347712357.USD","LU0353189763.USD","IE00BFSS7M15.SGD","IRE","LU0127658192.USD","LU1629891620.HKD","LU1989764664.SGD","BK4097","LU0345774391.USD","LU1988902786.USD","LU2756315664.SGD","IE00B894F039.SGD","LU1934455194.USD","LU0056508442.USD","LU0345774631.USD","LU1935042488.USD","3NVD.UK","LU1821325948.USD","BK4516","LU0096362180.USD","LU0557290698.USD","LU0133085943.USD","IE00BN29S564.USD","DIPS","LU0124676726.USD","LU1823568750.SGD","LU1169590202.USD","BK4539","LU0109391861.USD","LU1623119135.USD","AGOX","BK4532","LU2087625088.SGD","LU1935043536.SGD","BK4139","GAP","LU1814569148.SGD","AIPI","LU2125154935.USD","IE0004445239.USD","LU1043141396.HKD","LU2125909593.SGD","LU0528227936.USD","LU2244417387.USD","LU2360107671.USD","LU2168564495.EUR","BK4579","LU0251132253.USD","PYPG","SG9999000418.SGD","LU0072462426.USD","LU0187121727.USD","NVDA","LU1852331112.SGD","LU0882574139.USD","LU2491050154.USD","SMH","EFIV","LU0348723411.USD","LU1037948897.HKD","VT","LU0345769631.USD","LU0395794307.EUR","AIFD","LU0957791311.USD","LU0823434583.USD","LU1720051017.SGD","SG9999015952.SGD","BK4561","MRNA","LU2458330169.SGD","LU1668664300.SGD","LU2471134523.USD","SOXX","LU2860962120.EUR","IE00B19Z8W00.USD","SG9999014559.SGD","LU1400636657.SGD","LU1066051811.HKD","LU2750360641.GBP","LU0081259029.USD","LU0061475181.USD","LU1718418525.SGD","LU1983260115.SGD","TTXU","LU2505996681.GBP","LU2125154778.USD","USD","LU1064131342.USD","NVD2.UK","LU2083900584.USD","LU0106261372.USD","IE0004091025.USD","SGXZ31699556.SGD","CNEQ","LU1989772840.SGD","IE00B19Z8X17.USD","LU2054465674.USD","ANV","LU2487616109.SGD","LU0210533765.USD","LTL","NVYY","NVDQ","BK4568","CMAG","LU1202635105.USD","LU0154236417.USD","BK4141","LU0511384066.AUD","IDNA","ROM","IE000W1ABFV2.USD","LU1934455863.HKD","LU2360106780.USD","NVD","IE00B4JS1V06.HKD","BK4106","LU0787776722.HKD","BK4529","ULTA","LU0211327993.USD","BK4535","LU1732800096.USD","LU2413666426.HKD","LU0738911758.USD","IE0004445015.USD","LU0107464264.USD","LU0661504455.SGD","LU1261432733.SGD","LU1267930490.SGD","LU1868836914.USD","HERO","LU0726765562.USD","STCE","LU1861215975.USD","LU1935042991.SGD","LU0642271901.SGD","LU1244550577.SGD","BK4227","LU0426417589.USD","LGHT","LU2322448791.USD","LU2092937148.SGD","SOLS","LU1923622614.USD","LU0823414551.USD","BK4533","IE00B19Z9P08.USD","LU1232071149.USD","LU2077746001.SGD","LU2462591277.SGD","LU2746668461.USD","BK4534","WISE","LU2028103732.USD","IE00BZ199S13.USD","BK4094","LU2430703178.SGD","BK4551","LU2211815571.USD","LU1951198990.SGD","SG9999015978.USD","IE000YTNTUN2.SGD","LU1674673691.USD","LU0175139822.USD","IE00BQXX3C00.GBP","SGXZ23171101.USD","LU1571399168.USD","LU0048584097.USD","IE00BMPRXR70.SGD","BK4505","IE00BK4W5L77.USD","LU2471134879.HKD","LU2237443978.SGD","TTWO","LU2242650005.HKD","LU1992135399.USD","IE00B3M56506.USD","LU0198837287.USD","LU0472753341.HKD","IE00BDCRKT87.USD","LU2361044865.SGD","CHAT","LU0256863811.USD","METV","LU2097344431.USD","HK0000320264.USD","IE000ITXATA3.USD","LU1699723380.USD","LU0719512351.SGD","LU2286300806.USD","LU1642822529.SGD","LU0069063385.USD","LU0215105999.USD","LU0274383776.USD","BK4554","LU0345770993.USD","IREZ","LU2111349929.HKD","LU2361044949.HKD","SG9999014542.SGD","LU0466842654.USD","LU1035775433.USD","IXN","LU2063271972.USD","LU1861127337.USD","LU1804176565.USD","NULC","LU0444971666.USD","LU0345768153.USD","IE00BZ1G4Q59.USD","BNGE","IREX","BK4524","LU0795875169.SGD","LU2237438978.USD","JGRO","NVDO","LU1670756490.USD","LU0316494557.USD","LU2237443549.SGD","LU1244550494.USD","LU2092627202.USD","LU2271345857.HKD","LU2023250504.SGD","LU0310799852.SGD","FTEC","LU0320765059.SGD","LU0868494708.USD","LU0256863902.USD","LU2413666699.HKD","IE00BJTD4N35.SGD","LU0234572021.USD","NVDD","BK4560","LU0354030511.USD","LU1280957306.USD","NVDS.UK","TRFK","LU1235294995.USD","LU0820561909.HKD","LU1861217088.USD","IE00BFSS8Q28.SGD","PYPL","LU1791710400.SGD","SG9999014567.USD","LU0061474705.USD","BTAI","LU0354030438.USD","LU2237957811.SGD","IE00B3SWFQ91.USD","LU0128525929.USD","LU0070217475.USD","LU0342679015.USD","LU0553294199.USD","SNVDAmain","IE000KEQY171.SGD","LU1861220207.SGD","SGXZ80539844.SGD","LU2133065610.SGD","LU0203201768.USD","IE00B5TLWC47.USD","LU2954938101.SGD","IE00BK4W5M84.HKD","LU0861579265.USD","LU1939255532.USD","LU0949170772.SGD","LU0157215616.USD","LU0080751232.USD","LU1127390331.HKD","LU2065171402.SGD","LU0061474960.USD","LU0979878070.USD","LU1069347547.HKD","LU0210536198.USD","IE0003U64NQ7.SGD","LU0417517546.SGD","SG9999018865.SGD","IE0009G5SDU7.USD","LU2272731782.SGD","IE00BDRTCR15.USD","LU2237443382.USD","LU0097036916.USD","LU2361045086.USD","LU1066051225.USD","LU0823421333.USD","LU1119994496.HKD","LU2543165471.USD","NVDL","LU0795875086.SGD","LU1720051108.HKD","LU1934455277.USD","LU2065171311.SGD","SG9999015358.SGD","LU0345770308.USD","LU1914381329.SGD","LU0823411888.USD","VGT","LU0006306889.USD","LU2236285917.USD","LU0238689110.USD","CYTK","IE000Q6AESB8.SGD","LU1674673428.USD","IE0034235295.USD","IE00BD6J9T35.USD","LU0965509101.SGD","LU0964807845.USD","LU0994945656.USD","SNPE","BK4023","LU2505996509.AUD","LU0234570918.USD","SG9999015986.USD","LU2294711713.HKD","IBLC","LU1778281490.HKD","MRNY","LU1496350171.SGD","LU1951200564.SGD","ABFL","IE00BJJMRX11.SGD","LU2456880835.USD","LU1839511570.USD","TYLG","LU0965508806.USD","LU0158827948.USD","LU1691799644.USD","LU0323591593.USD","BK4592","LU1116320737.USD","LU1712237335.SGD","LU1880398554.USD","IE0005OL40V9.USD","LU2100268510.USD","NVII","LU0957808578.USD","BITQ","IREC","LU2125909247.SGD","BK4598","LU1366192091.USD","IE00BJLML261.HKD","NVC","LU2242649171.HKD","SG9999014575.USD","TEK","BK4550","LU2491050071.SGD","LU0345769128.USD","LU2326559502.SGD","LU0289739343.SGD","LU0820562030.AUD","LU2125910336.SGD","BK4605","BK4567","LU0820561818.USD","LU1732799900.SGD","LU2602419157.SGD","QNRX","LU2461242641.AUD","LU2417539215.USD","LU1046421795.USD","LU2473716301.USD","FAI","IE00BKDWB100.SGD","BK4587","LU1121112475.USD","WDNA","LU0323239441.USD","LU1803068979.SGD","GB00BDT5M118.USD","BK4503","BK4549","LU0323240290.USD","LU1267930573.SGD","LU2097344357.USD","IE0004086264.USD","SOXY","ADSK","LU1721428933.USD","BK4528","SNVD.UK","LU2463028550.USD","LU0823421416.USD","IE00B1XK9C88.USD","CHPX","SG9999002232.USD","IE00B5949003.HKD","FINX","LU2506951792.HKD","BK4600","LU2247934214.USD","LU2360032135.SGD","LU1992135472.HKD","NVDB","HK0000306701.USD","GAMR","HK0000819398.USD","LATR","FDIG","LU0225283273.USD","LU1429558221.USD","LU0029864427.USD","LU2290526834.HKD","BK4543","LU2433249047.HKD","LU0276348264.USD","LU0289960550.SGD","LU1923621640.USD","SG9999014898.SGD","LU1144417596.USD","LU1267930730.SGD","LU1923623000.USD","ILDR","LU2168564222.USD","SHOC","LU2265009873.SGD","IE0034235188.USD","IE00BJJMRY28.SGD","BK4581","LU1791807156.HKD","LU0943347566.SGD","LU1069344957.HKD","IE0009356076.USD","LU0203202063.USD","IE00BQXX3D17.EUR","LU0345768740.USD","RSPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662667970","title":"Success After a Century of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough","url":"https://stock-news.laohu8.com/highlight/detail?id=2662667970","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662667970?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:30","pubTimestamp":1787916600,"startTime":"0","endTime":"0","summary":"An mRNA cancer vaccine Moderna had been developing with Merck had hit its mark — the first success of a therapeutic cancer vaccine in late-stage testing after more than 100 years of failed attempts.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44N0PO:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRTS","LU1093756168.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0124676726.USD","LU1066051811.HKD","BK4533","RXL","LU2125909247.SGD","LU0980610538.SGD","LU1699723380.USD","LU1989772923.USD","LU0965509010.AUD","LU0130517989.USD","LU2360032135.SGD","LU0130102774.USD","LU0861579265.USD","SG9999002232.USD","LU0070302665.USD","SG9999014575.USD","LU1066051225.USD","BK4585","LU2361044949.HKD","LU0234572021.USD","BK4550","SG9999001440.SGD","VHT","LU2361045086.USD","LU1093756325.SGD","LU2089984988.USD","LU0477156953.USD","LU1057294990.SGD","LU2125154778.USD","LU0868494617.USD","LU0648001328.SGD","LGHT","LU1989771016.USD","LU0122379950.USD","LU1037948541.HKD","XLV","LU1116320901.HKD","LU0985320562.USD","LU2106854487.HKD","JDOC","LU1934455863.HKD","IE0009355771.USD","LU1934455194.USD","LU2361044865.SGD","IE00BBT3K403.USD","LU2491050154.USD","LU1923622614.USD","BK4568","LU2461242641.AUD","SG9999015341.SGD","WDNA","IE00BLSP4239.USD","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0289739699.SGD","LU0859254822.USD","LU1066051498.USD","LU1983299246.USD","LU0211331839.USD","LU0208291251.USD","IE000M9KFDE8.USD","BMED","LU1201861249.SGD","MRNX","BK4588","LU0203347892.USD","PPH","LU1974910355.USD","LU1571399168.USD","TRUH","PAWZ","BK4551","SG9999014542.SGD","LU1430594728.SGD","SG9999001176.USD","LU2125154935.USD","LU0265550359.USD","LU0823416689.USD","LU2357627491.SGD","SG9999014559.SGD","LU0965508806.USD","LU0965509283.SGD","LU1023059063.AUD","IE0002141913.USD","LU2125909593.SGD","IYH","LU0098860793.USD","LU0942090050.USD","LU0106261372.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU1929549753.HKD","IDNA","GNOM","LU0965509101.SGD","LU0432979614.USD","BK4534","LU2468319806.SGD","LU2491050071.SGD","LU2491049909.HKD","LU1066053197.SGD","MRNA","BK4548","IE00BN8TJ469.HKD","LU1291159041.SGD","LU1989772840.SGD","LU2023250504.SGD","LU1941712348.USD","BK4559","SG9999001176.SGD","LU1069347547.HKD","LU1061106388.HKD","BK4516","LU1035773651.USD","IE00BSNM7G36.USD","LU0320765646.SGD","LU1585245621.USD","LU1917777945.USD","LU0266013472.USD","LU2023250843.SGD","SG9999015358.SGD","LU1941712264.USD","FTXH","BK4007","LU2433249047.HKD","BK4501","LU0203345920.USD","MRNY","SGXZ57979304.SGD","IE00B2B36J28.USD","BK4139","SG9999014567.USD","LU0868494708.USD","GDOC","IE00B4R5TH58.HKD","BK4532","LU0006306889.USD","LU2324357040.USD","LU0058720904.USD","LU0689626769.HKD","LU1037948897.HKD","LU0238689110.USD","LU1934455277.USD","FHLC","IXJ","LU1116320737.USD","LU1162221912.USD","MRK","IHE","IE00BFTCPJ56.SGD","LU0265550946.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662389067","title":"Moderna Prices $2.6 Billion Convertible Notes due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2662389067","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662389067?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:23","pubTimestamp":1787916190,"startTime":"0","endTime":"0","summary":"Moderna  priced a $2.6 billion offering of convertible senior notes due 2032, up from the previously announced $2 billion, the company said Friday.Initial purchasers were granted an option to buy up to an additional $400 million of notes, the company said.The company expects to use the net proceeds to pay the cost of certain capped call transactions and for general corporate purposes, including potential investments in its oncology business and debt repayment, it added.The company expects the sale to initial purchasers to close Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4588","BK4139","GNOM","LGHT","BK4533","WDNA","MRNY","MRNA","IDNA","BK4568","BK4501","BK4585","MRNX","BK4532","BK4548","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062748","title":"Moderna Rises After Upsized $2.6 Bln Convertible Bond Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062748","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662062748?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:19","pubTimestamp":1787915947,"startTime":"0","endTime":"0","summary":"BUZZ-Moderna rises after upsized $2.6 bln convertible bond sale** Biotech firm Moderna'sMRNA.Oshares up 1.2% at $144.50 before the bell on Fri after it raises more capital than planned** Cambridge, Massachusetts-based MRNA announces pricing private offering of $2.6 bln 0% convertible bonds due March 1 2032** Conversion price of $210.58 represents 47.5% premium over stock's last close of $142.77** MRNA shares finished down 4.6% on Thurs after counveiled$2 bln offering for general corp purposes, including to grow its oncology business and repay debt** Co expects to use approx $285 mln of net proceeds to pay cost of capped call transactions; cap price of $392.62 is 175% above stock's last sale** On Aug 19, MRNA shares soared 177% to $174.38, a 3-1/2 year high, after co said itsskin cancer vaccine, combined with Merck'sMRK.NKeytruda, reduced risk of recurrence and spread of melanoma in a late-stage trial** Through Thurs, MRNA shares up 384% YTD** Avg rating of 23 analysts is \"hold\"; median","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL6N44P0MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","BK4501","BK4568","BK4548","BK4534","BK4585","IDNA","BK4139","BK4532","WDNA","BK4551","BK4588","MRNA","BK4533","MRNY","LGHT","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061139","title":"Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061139","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061139?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:26","pubTimestamp":1787912783,"startTime":"0","endTime":"0","summary":"Incyte  partner Knight Therapeutics has submitted a supplemental application to the Brazilian health regulatory agency seeking approval for an additional indication for Minjuvi in combination with other medicines as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.The drug combination consists of Minjuvvi and lenalidomide added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the company said.The application is meant to expand Minjuvi in earlier lines of cancer therapy in Brazil, the company said.The supplemental submission is based on previous approvals and results from a phase 3 trial, the company said.Knight has exclusive supply and distribution rights for Incyte's Minjuvi, which is also called Monjuvi, in the US and parts of Latin America, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWZS","BK4532","BK4139","IDNA","BK4588","INCY","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145744656","title":"US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1145744656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145744656?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:24","pubTimestamp":1787912643,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has officially approved Revolution Medicines' self-developed pancreatic cancer treatment, Rasonque, this week. This approval represents a significant triumph for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","LABU","LU0889565916.HKD","BBH","CANC","IE0009354923.USD","LU0320765992.SGD","PTH","IDNA","IE0002141913.USD","IE00BJJMRZ35.SGD","RVMD","BK4585","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037671","title":"Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662037671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:21","pubTimestamp":1787880060,"startTime":"0","endTime":"0","summary":"Earlier this year, an oncology biotech with no drugs on the market-just promising research-was attracting takeover interest. Revolution Medicines stayed independent.This week, that bet paid off.The 12","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","PTH","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","IE00B4R5TH58.HKD","IE0002141913.USD","CANC","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","RVMD","LU0889565916.HKD","IDNA","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662035516","title":"FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2662035516","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662035516?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:04","pubTimestamp":1787864640,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration approved new seasonal Covid-19 vaccine formulas made by Moderna, Pfizer and BioNTech.The agency gave a green light to supplemental biologics license applications for the 2026-2027 formulas to the Comirnaty vaccine, made by Pfizer and BioNTech, and Moderna's mNexspike and Spikevax shots. The new formulas are designed to target the XFG variant of Covid-19.Pfizer and BioNTech said the new formulation of its vaccine would begin shipping immediately for use beginning in the fall. Moderna said its updated vaccines will be available in the coming days.All three vaccines were approved for adults 65 years of age and older. The FDA also approved the shots for individuals younger than 65 whose underlying conditions put them at high risk for severe outcomes from Covid-19. Those approvals extend as young as 12 years old for mNexspike, five years for Comirnaty, and six months for Spikevax.\"Our updated COVID-19 vaccines help protect those at high risk of severe diseas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","IDNA","LU0306807586.USD","LU1023059063.AUD","IE00BBT3K403.USD","BK4533","IE00B3T34201.USD","SG9999013999.USD","LU0456855351.SGD","LU2596442595.SGD","SG9999002232.USD","BK4007","SG9999011175.SGD","BK4551","PFE","IE00BLSP4239.USD","LU0225771236.USD","LU0234572021.USD","LU1894683348.USD","LU1066053197.SGD","WDNA","SG9999001176.SGD","BK4534","BK4568","LU0225284248.USD","IE0002270589.USD","BK4599","IE00BLSP4452.SGD","LGHT","MRNX","LU0321505868.SGD","LU0321505439.SGD","SG9999002224.SGD","OZEM","SG9999001176.USD","LU1894683264.USD","BK4588","BNTX","MRNY","BK4585","LU0985481810.HKD","SGXZ57979304.SGD","BK4535","BK4592","LU1057294990.SGD","LU0289739699.SGD","BK4548","LU0170899867.USD","GNOM","LU0058720904.USD","BK4532","LU0306806265.USD","LU0122379950.USD","LU1883839398.USD","LU1066051498.USD","MRNA","SG9999003800.SGD","LU0868494617.USD","BK4139","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4581","BK4550","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033626","title":"Moderna Inc. Stock Slips 4.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:34","pubTimestamp":1787862840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 4.6% to $142.77 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.6% to 26,541.35 and the Dow Jones Industrial Average rising 0.2% to 53,569.44.This was the stock's second consecutive day of losses.Moderna Inc. closed 19.2% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $265.77, Pfizer Inc. fell 1.0% to $28.02, and Gilead Sciences Inc. rose 0.52% to $148.86.Trading volume totaled 24.9 million, compared to the 50-day average of 16.4 million.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0861579265.USD","BK4583","BBH","LU1934455277.USD","LGHT","LU0889565916.HKD","BK4533","MRNY","LU1061106388.HKD","BK4534","IBBQ","LU1037948541.HKD","LU1674673691.USD","IE00BKVL7J92.USD","MRNA","LU0320765992.SGD","LU0114720955.EUR","LU1571399168.USD","LU1674673428.USD","TMED","LU1066053197.SGD","LU2468319806.SGD","BK4568","BK4139","LU0965508806.USD","IDNA","BK4550","SG9999015952.SGD","SG9999015986.USD","GNOM","MEDI","GILD","IBB","LU1934455194.USD","MRNX","LU0109394709.USD","BIB","BK4588","IE00B7SZLL34.SGD","BMED","IE00B19Z3581.USD","LU2324357040.USD","LU0965509283.SGD","LU2357627491.SGD","SG9999015945.SGD","LU0965509010.AUD","BK4551","WDNA","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403857","title":"Twist Bioscience CEO Emily Leproust Sells USD 6.28 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403857","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403857?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:06","pubTimestamp":1787861174,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO Emily Leproust sells USD 6.28 million in common sharesTwist Bioscience CEO Emily M. Leproust sold 41,570 shares on Aug. 25, 2026 at $150.56 to $154.45.Direct holdings fell to 770,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL4CsHyC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Twist Bioscience CEO Emily Leproust Sells USD 6.28 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TWST","BK4139","BK4585","IDNA","WDNA","ARKG","GNOM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":3,"totalSize":323,"code":"91000000","status":"200"}]}}